Has anyone tried to sell you peptides recently? Probably not. But they will.
Once a niche obsession for bodybuilders and biohackers in the basement gyms, peptides are now hyped by fringe influencers and the US Secretary of Health and Human Services, Robert F. Kennedy Jr. The hype is shifting from curiosity to a commercial gold rush. The FDA is holding hearings on July 23 and 24 to decide if certain peptides should be reclassified. If they do, pharmacies can legally compound them. Custom mixes would become legal. This move would reverse a 2023 Biden-era ban that stopped compounding these substances.
Career scientists at the agency say no. Industry insiders say the answer is yes.
The committee assessing this includes peptide boosters. The outcome seems pre-written. Telehealth companies are already assuming the floodgates will open. “We’re getting everything ready,” says Myra Ahmad, CEO of Mochi Health. The platform originally focused on GLP-1s. Now, pharmacies are finalizing safety tests. Pricing is being crunched.
Some virtual health giants waited for this. Hims & Hers Health bought a manufacturing facility in February 2026. They are developing clinical protocols. Anant Vinjamoori, Hims’ chief medical officer, will testify at the hearing. Joshua Fritzler of Olympia Pharmaceuticals says they spent “a lot of money” creating formulas. They are ready if the FDA gives the nod.
There’s an understanding in the industry that a massive shift is imminent.
The GLP-1 boom taught Americans to inject medications at home. It also turned pharmacies into cash cows. Now, they want more. Cole Thomas of RxConnexion notes that compounding clients are testing popular peptides. One is BPC-157. It’s touted as a healing compound. It’s half of the “Wolverine stack.” BPC stands for body protection compound.
Sapho Bio has been approached to test these peptides too. Cameron Bravo, a researcher there, confirms their clients want validation. They need proof the mixtures are clean and sealed. Sapho Bio has tested BPC-157 and MOTS-c. Evangelists call the latter “exercise in a vial.” Pharmacies are spending big. “They’re probably investing $100,000 before they’re even out,” Bravo says.
Approval isn’t immediate green-light magic. There is a review period. The FDA proposes rules. The public comments. It is long-winded. Gerard Olson, formerly at LegitScript, warns of the delay.
Hims plans to wait. “We don’t want to be first to market,” Vinjamoori says. “We want to be best in the market.”
Others aren’t waiting. Amanecia Health in Texas and Virginia started prescribing BPC-157 already. Founder Ann Czarnik sees the trend on Instagram. Her practice is tentatively prescribing these substances to a small group. She stresses they are not FDA-approved. She cannot advertise this yet. The data is lacking. The risk is real.
Scott Brunner of the Alliance for Pharmacy Compounding is warning members. Don’t go rogue. Don’t roll out peptides early. Prescribers are being hammered. Patients are demanding them. The temptation is intense. The gray market is everywhere.
Right now, getting your hands on these substances is shockingly easy. Online sellers list them as “research-grade only.” The disclaimers scream: not for human consumption. Olympia’s Fritzler calls the gray market insane. “We are not participating.”
Thomas Millman runs OnTop Labs in Florida. He sells research-use peptides like Melanotan II. People call it the “Barbie peptide.” The “tan jab.” It stimulates melanin. It changes skin color. It faces FDA discussion in 2027, not now. The Skin Cancer Foundation warns of melanoma risks.
Millman still promotes on TikTok. Competition is fierce. “There’s just so much more,” he says. Everyone wants a piece of the pie. The rush is on. Whether you end up injecting your way to Wolverine-like healing or just a tan and a potential health scare is the real question. The cash grab has begun. You’re just now noticing the door opening.
